Extracellular vesicles: a growing pipeline still searching for validation
## Newsletter Signup - Under Article / In Page
"*" indicates required fields
Phone
This field is for validation purposes and should be left unchanged.
## Subscribe to our newsletter to get the latest biotech news!
By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*
Company name*
Job title*
Business email*
**Exosomes first drew attention as a kind of ready-made biological delivery system. They’re membrane-bound particles produced by cells, able to carry proteins and nucleic acids, shield cargo in transit, and in some cases interact with specific target cells through surface features inherited from their parent cells. That combination helped make them attractive both as therapeutics in their own right and as delivery vehicles for harder-to-handle payloads. More broadly, the field now tends to speak of extracellular vesicles (EVs) rather than exosomes alone.**
That early promise, however, has run into difficulties as the science proved to be hard to translate. EV-based therapeutics have generated a large research and clinical pipeline, but they still have not produced an approved drug. A review from Nature noted that more than 100 clinical studies worldwide were evaluating natural and engineered EV drugs, while also noting persistent technical and regulatory barriers, from mechanism and scale-up to product definition.
So the field looks different today than it did a few years ago. The question is where EV therapeutics are actually gaining traction, and what kind of product has the best chance of working: relatively native vesicles meant to reproduce regenerative or anti-inflammatory signals, or more heavily engineered vesicles designed as defined delivery systems.
### Table of contents
## What are exosomes now, exactly? And why the field increasingly says EVs
The term “exosome” is still widely used, but in practice, most work in the field now falls under the broader category of EVs.
EVs are membrane-bound particles released by cells that carry proteins, RNA, and other biomolecules. Exosomes are one subtype within that group, defined by their formation inside the cell through the endosomal pathway. The problem is that, outside of very controlled systems, it is difficult to prove that a given vesicle population truly comes from that pathway.
That is why recent guidelines, including MISEV2023, recommend using “extracellular vesicle” unless the origin of the vesicles has been clearly demonstrated. In practice, many so-called exosome preparations are heterogeneous mixtures of vesicles and other extracellular material, shaped as much by how they are produced and isolated as by their biological origin.
It is not just a naming issue; if two products labeled as “exosomes” are produced from different cell types or purified using different methods, they may have very different compositions and effects. That makes it harder to compare results across studies, define potency, and establish consistent manufacturing standards challenges that come up repeatedly as EV-based therapies move into the clinic.
## The exosome therapy field has split into three therapeutic models
A few years ago, exosome therapy was often pitched as a natural delivery system that might also have therapeutic effects of its own. That is no longer really how the field looks. The more useful way to read it now is as three partly overlapping models: native or minimally modified EVs used for repair and immune modulation; engineered EVs used as delivery systems; and EV-based vaccine or immune platforms.
## Suggested Articles
## Six exosome therapy companies driving development in the field
### Regenerative and immunomodulatory EVs
This is probably the closest branch to the original exosome narrative. The idea is to capture some of the useful biology associated with mesenchymal stromal cells (MSCs) in a cell-free format. On paper, it aims to keep the anti-inflammatory and pro-repair signals, and lose some of the logistical and safety complications that come with living-cell therapy. This is still one of the strongest translational fits for EV therapeutics, especially in wound healing, inflammatory disease and acute tissue injury, even if the clinical evidence remains hard to compare across studies.
Aegle Therapeutics is a good example. Its lead candidate, AGLE-102, is an allogeneic EV product derived from donor MSCs and is being developed for recessive dystrophic epidermolysis bullosa, a severe blistering skin disease. The candidate is currently in phase 1/2.
Direct Biologics pursues the same general idea into a more systemic setting. Its candidate ExoFlo is an MSC-derived EV product that the company is taking into acute respiratory distress syndrome (ARDS), with a pivotal phase 3 trial in ARDS currently enrolling. If MSC-derived vesicles can dampen inflammation and support tissue recovery, then severe inflammatory lung injury is one of the places where they should have room to work. But ARDS is clinically messy, EV products are hard to standardize, and even relatively advanced programs have not yet translated into an approved product.
So this first model is best understood as cell therapy without the cells. It remains the most intuitive use case for EVs, but also one where broad biological activity can make mechanism, potency and consistency harder to pin down. The biology looks plausible, the safety profile often looks manageable, but efficacy signals are still uneven, and the studies are highly heterogeneous.
### Engineered EVs as delivery vehicles
Here, EVs are not valued mainly for their native cargo but for what can be deliberately put inside them or displayed on their surface. This is where the field makes its strongest case against viral vectors and lipid nanoparticles. EVs are presented as biologically derived carriers that may be redosable, less immunogenic, and potentially better suited to difficult tissues such as the central nervous system (CNS).
Evox Therapeutics, which was once framed more broadly as an exosome delivery player, is now centered on genetically driven neurodegenerative disease. Its current platform, ExoEdit, combines exosome-based transport with a CRISPR-based editing approach, and the company says it is advancing programs against MSH3 and ATXN2. The pitch is that exosomes may offer a way to get gene-editing tools into the CNS with a safety and access profile that could differ from current viral and LNP approaches.
ILIAS Biologics sits slightly differently in the same category. Its lead candidate, ILB-202, is an engineered allogeneic EV derived from HEK293 cells and loaded with the anti-inflammatory protein super-repressor IκB. That makes it less of a pure delivery platform story and more of a deliberately designed EV therapeutic. The candidate is currently in phase 1.
Carmine Therapeutics is another example. Its platform is built around red blood cell extracellular vesicles, or RBCEVs, rather than the more familiar MSC-derived systems. The company presents these vesicles as a way around some of the standard challenges of viral delivery, including immunogenicity, limited cargo size and manufacturing complexity. It also emphasizes that RBCEVs can be loaded with nucleic acids and surface-modified for targeting.
### EV-based vaccines and immune modulation
EVs are not only being used to repair tissue or carry therapeutic payloads. They are also being explored as immune platforms, able to present antigens or act as biologically derived carriers in vaccine design.
Capricor Therapeutics is one of the clearest examples. Its platform has entered a first-in-human phase 1 trial, with the first subjects dosed in August 2025. Company updates in March 2026 said that preliminary data suggested the vaccine had been well tolerated across tested doses. That does not make EV vaccines validated yet, but it does show that the field is extending beyond regenerative medicine and cargo delivery.
## Clinical reality check: a broad pipeline, but still limited validation
There are more than 90 registered therapeutic EV clinical trials as of 2024, which is enough to show that the modality has moved beyond a purely preclinical story. But that number can also mislead. The pipeline is still dominated by early-stage studies, products are highly heterogeneous, and comparing one program with another is often difficult because “EV therapy” can refer to very different things: MSC-derived preparations, engineered vesicles carrying a defined payload, or more complex exosome-based platforms. That breadth is part of the field’s appeal, but it also makes it hard to read the pipeline as a coherent body of evidence.
The strongest signals so far come from more defined or context-specific uses, while broader platform ambitions remain largely unproven. For now, the field looks more like a collection of experiments still searching for where it works best.
### This article is reserved for subscribers
### Subscribe for free to continue reading.
Enter your details to log in or subscribe.
Email
Company name
Job title
Continue Reading
or
Continue with Microsoft Continue with LinkedIn
By continuing, I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.
Organoids in cancer research: Paving the way for faster drug development across cancer indications
This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever.
Watch now
Explore other topics: CancerVaccines
ADVERTISEMENT
Extracellular vesicles: a growing pipeline still searching for validation Exosome therapy has emerged as a solution to deliver treatments safely and effectively, and as a new approach to regenerati...
#In #Depth #Cancer #Vaccines
Origin | Interest | Match
0
0
0
0
